Chronic Renal Failure Therapeutics

Chronic Renal Failure Therapeutics


Global Chronic Renal Failure Therapeutics Market to Reach US$22.9 Billion by 2030

The global market for Chronic Renal Failure Therapeutics estimated at US$20.1 Billion in the year 2023, is expected to reach US$22.9 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2023-2030. Antihypertensive Drugs, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$16.3 Billion by the end of the analysis period. Growth in the Antianemia Drugs segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 4.0% CAGR

The Chronic Renal Failure Therapeutics market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.4% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Chronic Renal Failure Therapeutics Market - Key Trends and Drivers Summarized

Chronic renal failure, also known as chronic kidney disease (CKD), is a progressive condition characterized by the gradual loss of kidney function over time. This debilitating disease affects millions worldwide, leading to serious health complications such as cardiovascular disease, anemia, and bone disorders. The primary goal of therapeutics for CKD is to slow disease progression, manage symptoms, and improve the quality of life for patients. Early-stage treatments often include lifestyle modifications such as dietary changes, exercise, and blood pressure control. Medications like angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are commonly prescribed to control hypertension and reduce proteinuria, which helps to preserve kidney function. Additionally, diabetes management is crucial in CKD patients, as hyperglycemia can exacerbate kidney damage.

As CKD progresses to more advanced stages, therapeutic strategies become more complex and intensive. Anemia management often involves the use of erythropoiesis-stimulating agents (ESAs) and iron supplements to boost red blood cell production and alleviate fatigue. Mineral and bone disorder management is addressed through phosphate binders, vitamin D analogs, and calcimimetics to maintain mineral balance and bone health. For patients reaching end-stage renal disease (ESRD), renal replacement therapies such as dialysis and kidney transplantation become necessary. Hemodialysis and peritoneal dialysis are life-sustaining treatments that perform the filtration functions of the kidneys, while transplantation offers a potential cure but requires lifelong immunosuppression to prevent organ rejection.

The growth in the chronic renal failure therapeutics market is driven by several factors, including the increasing prevalence of CKD due to rising rates of diabetes, hypertension, and aging populations. Technological advancements in diagnostic tools have improved the early detection of CKD, enabling timely intervention and better disease management. Consumer behavior towards proactive health management and regular screenings has also contributed to the early diagnosis and treatment of CKD. Additionally, significant investments in research and development by pharmaceutical companies have led to the introduction of novel therapies and improved formulations of existing drugs. Regulatory support and favorable reimbursement policies have further facilitated the adoption of advanced CKD treatments. The expansion of healthcare infrastructure, particularly in emerging economies, has increased access to CKD therapeutics and renal replacement therapies. These factors collectively ensure a dynamic and growing market for chronic renal failure therapeutics, aiming to enhance patient outcomes and extend the lives of those affected by this chronic condition.

Select Competitors (Total 37 Featured) -
  • Akebia Therapeutics, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Siemens Healthineers AG;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Chronic Renal Failure Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Kidney Failure Associated With Rising Global Prevalence of Diabetes and Hypertension Spurs Demand for Renal Failure Therapeutics
Advances in Dialysis Technology Enhance Treatment Efficacy and Patient Comfort
Development of Novel Pharmacologic Treatments to Delay Kidney Disease Progression
Growing Focus on Preventive Healthcare Measures & Expansion of Renal Disease Awareness Programs Bolster Early Intervention Efforts & Diagnosis Rates
Impact of Aging Population on Healthcare Systems and Renal Therapy Needs
Advancements in Gene Therapy and Stem Cell Research Open New Treatment Avenues
Global Health Initiatives Aimed at Improving Access to Renal Care to Benefit Market Growth
Review of the Economic Burden of Chronic Renal Failure
Innovations in Kidney Transplant Procedures and Immunosuppressive Therapies
Shift Towards Personalized Medicine in Managing Chronic Kidney Disease
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Chronic Renal Failure Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Antihypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Antihypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Antihypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Antianemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Antianemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Antianemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
JAPAN
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
CHINA
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
EUROPE
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
FRANCE
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
GERMANY
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
SPAIN
TABLE 44: Spain Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Spain Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Spain 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
RUSSIA
TABLE 47: Russia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Russia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Russia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of Europe Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
AUSTRALIA
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 59: Australia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Australia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Australia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
INDIA
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 62: India Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: India Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: India 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 65: South Korea Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: South Korea Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: South Korea 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Rest of Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
LATIN AMERICA
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 71: Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 72: Latin America Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 74: Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 77: Argentina Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Argentina Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Argentina 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
BRAZIL
TABLE 80: Brazil Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Brazil Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Brazil 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
MEXICO
TABLE 83: Mexico Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Mexico Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Mexico 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Latin America Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
MIDDLE EAST
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 89: Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 90: Middle East Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 92: Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
IRAN
TABLE 95: Iran Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Iran Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Iran 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
ISRAEL
TABLE 98: Israel Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Israel Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Israel 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Saudi Arabia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Saudi Arabia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 104: UAE Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: UAE Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: UAE 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Middle East Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
AFRICA
Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 110: Africa Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Africa Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Africa 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings